.jpg)
Use of PI3K inhibitors for the treatment of obesity, steatosis and ageing
WO2012052730
The inventors have found a method to treat or prevent diseases such as obesity, obesity-associated diseases or conditions, steatosis and biological aging by using a phosphoinositide 3-kinase (PI3K) inhibitor. The CNIO has developed a method to treat or prevent diseases or conditions associated with the expression of peroxisome proliferator-activated receptor gamma coactivator 1-a (Pgcl a) and/or uncoupling protein 1 (Thermogenin or Ucp1 ) in brown adipocytes, by the use of a phosphoinositide 3-kinase (PI3K) inhibitor (PI3Ki).
The present invention has surprisingly found the impact of PI3K signalling in the brown adipose tissue and in mammalian longevity. The PI3Ki of the present invention activate brown adipocytes in vitro and decrease body weight in obese mice. The PI3Ki of the present invention are useful in the treatment or prevention of obesity, obesity-associated diseases (such as type 2 (adult-onset) diabetes, high blood pressure, stroke, heart attack, heart failure, gallstones gout and gouty arthritis, osteoarthritis, sleep apnea and Pickwickian syndrome), steatosis, and also in reducing ageing.